S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$4.11
+0.04 (+0.98 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.99
Now: $4.11
$4.28
50-Day Range
$3.41
MA: $3.96
$4.97
52-Week Range
$0.88
Now: $4.11
$9.02
Volume2.33 million shs
Average Volume2.93 million shs
Market Capitalization$348.98 million
P/E RatioN/A
Dividend YieldN/A
Beta3.15
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma logo

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

587th out of 1,928 stocks

Pharmaceutical Preparations Industry

291st out of 774 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone267-469-0914
Employees78

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.01 million
Book Value($1.00) per share

Profitability

Net Income$-153,720,000.00
Net Margins-1,163.48%

Miscellaneous

Market Cap$348.98 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$4.11
+0.04 (+0.98 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

How has Arbutus Biopharma's stock price been impacted by Coronavirus?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABUS stock has increased by 59.3% and is now trading at $4.11.
View which stocks have been most impacted by COVID-19
.

Is Arbutus Biopharma a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Arbutus Biopharma's CEO?

1,428 employees have rated Arbutus Biopharma CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Arbutus Biopharma's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.05. The biopharmaceutical company earned $1.52 million during the quarter, compared to the consensus estimate of $1.81 million.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

6 brokers have issued 12 month price targets for Arbutus Biopharma's shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Arbutus Biopharma's stock price to reach $6.50 in the next year. This suggests a possible upside of 58.2% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view Wall Street analyst' top-rated stocks.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a increase in short interest in December. As of December 31st, there was short interest totaling 2,950,000 shares, an increase of 37.9% from the December 15th total of 2,140,000 shares. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is currently 1.0 days.
View Arbutus Biopharma's Short Interest
.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • Mr. William H. Collier, Pres, CEO & Director (Age 60, Pay $542.14k)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 59, Pay $551.14k)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 62, Pay $567.24k)
  • Pam Murphy, Investor Relations Consultant
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 66)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 57)
  • Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 46)
  • Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C, Sec. (Age 69)

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.11.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $348.98 million and generates $6.01 million in revenue each year. The biopharmaceutical company earns $-153,720,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Arbutus Biopharma employs 78 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.